https://www.selleckchem.com/pr....oducts/pluripotin-sc
12% (NNT= 835). The absolute risk reduction needed to maintain cost-effectiveness did not change with varying initial infection rates and remained less than 0.40% (NNT= 263) for infection treatment costs as low as $10,000 and less than 0.80% (NNT= 129) for dressing prices as high as $200. The use of silver-impregnated occlusive dressings is a cost-effective measure for infection prophylaxis after TKA and THA. The use of silver-impregnated occlusive dressings is a cost-effective measure for infection prophylaxis after TKA and THA.
Like
Comment
Share
